Advances in Ocular Drug Delivery Systems

Overview

Journal Eye (Lond)

Specialty Ophthalmology

Date 2020 Feb 20

PMID 32071402

Citations 47

Authors

Jennifer J Kang-Mieler

Kayla M Rudeen

Wenqiang Liu

William F Mieler

Affiliations

Soon will be listed here.

Abstract

Recent advances in pharmacological agents have led to successful treatment of a variety of retinal diseases such as neovascular age-related macular degeneration (AMD), diabetic macular oedema (DMO), and retinal vascular occlusions (RVO). These treatments often require repeated drug injections for an extended period of time. To reduce these repeated treatment burdens, minimally invasive drug delivery systems are needed. An ideal therapy should maintain effective levels of drug for the intended duration of treatment following a single application, recognising that a significant number of months of therapy may be required. There are numerous approaches under investigation to improve treatment options. This review will highlight the advantages and limitations of selected drug delivery systems of novel biomaterial implants and depots. The main emphasis will be placed on less invasive, longer acting, sustained release formulations for the treatment of retinal disorders.

Citing Articles

Non-Viral Delivery Systems to Transport Nucleic Acids for Inherited Retinal Disorders.

Jony M, Joshi A, Dash A, Shukla S Pharmaceuticals (Basel). 2025; 18(1).

PMID: 39861150 PMC: 11768406. DOI: 10.3390/ph18010087.

Undaria pinnatifida fucoidan extract inhibits activation of the NF-κB signaling pathway by herpes simplex virus type 1 and prevents amyloid-β peptide synthesis in retinal pigment epithelium cells.

Giuliani M, Uboldi C, Dellatorre F, Latour E, Ponce N, Stortz C Arch Virol. 2025; 170(2):27.

PMID: 39762563 DOI: 10.1007/s00705-024-06212-2.

Promising Pharmacological Interventions for Posterior Capsule Opacification: A Review.

Liu Y, Dong X, Wu B, Cheng Z, Zhang J, Wang J Glob Chall. 2024; 8(12):2400181.

PMID: 39679290 PMC: 11637782. DOI: 10.1002/gch2.202400181.

Recent updates on drug delivery approaches for improved ocular delivery with an insight into nanostructured drug delivery carriers for anterior and posterior segment disorders.

Khan S, Do C, Ho E Drug Deliv Transl Res. 2024; .

PMID: 39674854 DOI: 10.1007/s13346-024-01756-x.

Evaluating the efficacy and safety of polyglycolic acid-loading mitomycin nanoparticles in inhibiting the scar proliferation after glaucoma filtering surgery.

Li T, Tang J, Li C, Liu G, Li Y, Guo S Ann Med. 2024; 57(1):2436458.

PMID: 39632730 PMC: 11622377. DOI: 10.1080/07853890.2024.2436458.

References

Cunha-Vaz J, Bernardes R, Lobo C . Blood-retinal barrier. Eur J Ophthalmol. 2012; 21 Suppl 6:S3-9. DOI: 10.5301/EJO.2010.6049. View

Campbell M, Humphries P . The blood-retina barrier: tight junctions and barrier modulation. Adv Exp Med Biol. 2013; 763:70-84. View

Yasukawa T, Ogura Y, Tabata Y, Kimura H, Wiedemann P, Honda Y . Drug delivery systems for vitreoretinal diseases. Prog Retin Eye Res. 2004; 23(3):253-81. DOI: 10.1016/j.preteyeres.2004.02.003. View

Kang-Mieler J, Osswald C, Mieler W . Advances in ocular drug delivery: emphasis on the posterior segment. Expert Opin Drug Deliv. 2014; 11(10):1647-60. DOI: 10.1517/17425247.2014.935338. View

Yang C, Tirucherai G, Mitra A . Prodrug based optimal drug delivery via membrane transporter/receptor. Expert Opin Biol Ther. 2001; 1(2):159-75. DOI: 10.1517/14712598.1.2.159. View

Raghava S, Hammond M, Kompella U . Periocular routes for retinal drug delivery. Expert Opin Drug Deliv. 2005; 1(1):99-114. PMC: 11864216. DOI: 10.1517/17425247.1.1.99. View

Lewis R, von Wolff K, Tetz M, Koerber N, Kearney J, Shingleton B . Canaloplasty: circumferential viscodilation and tensioning of Schlemm canal using a flexible microcatheter for the treatment of open-angle glaucoma in adults: two-year interim clinical study results. J Cataract Refract Surg. 2009; 35(5):814-24. DOI: 10.1016/j.jcrs.2009.01.010. View

Olsen T, Feng X, Wabner K, Conston S, Sierra D, Folden D . Cannulation of the suprachoroidal space: a novel drug delivery methodology to the posterior segment. Am J Ophthalmol. 2006; 142(5):777-87. DOI: 10.1016/j.ajo.2006.05.045. View

Olsen T, Feng X, Wabner K, Csaky K, Pambuccian S, Cameron J . Pharmacokinetics of pars plana intravitreal injections versus microcannula suprachoroidal injections of bevacizumab in a porcine model. Invest Ophthalmol Vis Sci. 2011; 52(7):4749-56. PMC: 3175963. DOI: 10.1167/iovs.10-6291. View

10.

Rizzo S, Ebert F, Di Bartolo E, Barca F, Cresti F, Augustin C . Suprachoroidal drug infusion for the treatment of severe subfoveal hard exudates. Retina. 2011; 32(4):776-84. DOI: 10.1097/IAE.0b013e3182278b0e. View

11.

Grzybowski A, Told R, Sacu S, Bandello F, Moisseiev E, Loewenstein A . 2018 Update on Intravitreal Injections: Euretina Expert Consensus Recommendations. Ophthalmologica. 2018; 239(4):181-193. DOI: 10.1159/000486145. View

12.

Shima C, Sakaguchi H, Gomi F, Kamei M, Ikuno Y, Oshima Y . Complications in patients after intravitreal injection of bevacizumab. Acta Ophthalmol. 2007; 86(4):372-6. DOI: 10.1111/j.1600-0420.2007.01067.x. View

13.

Bourges J, Bloquel C, Thomas A, Froussart F, Bochot A, Azan F . Intraocular implants for extended drug delivery: therapeutic applications. Adv Drug Deliv Rev. 2006; 58(11):1182-202. DOI: 10.1016/j.addr.2006.07.026. View

14.

Lim J, Wolitz R, Dowling A, Bloom H, IRVINE A, Schwartz D . Visual and anatomic outcomes associated with posterior segment complications after ganciclovir implant procedures in patients with AIDS and cytomegalovirus retinitis. Am J Ophthalmol. 1999; 127(3):288-93. DOI: 10.1016/s0002-9394(98)00443-7. View

15.

Ebrahim S, Peyman G, Lee P . Applications of liposomes in ophthalmology. Surv Ophthalmol. 2005; 50(2):167-82. DOI: 10.1016/j.survophthal.2004.12.006. View

16.

Emerich D, Thanos C . NT-501: an ophthalmic implant of polymer-encapsulated ciliary neurotrophic factor-producing cells. Curr Opin Mol Ther. 2008; 10(5):506-15. View

17.

Tao W . Application of encapsulated cell technology for retinal degenerative diseases. Expert Opin Biol Ther. 2006; 6(7):717-26. DOI: 10.1517/14712598.6.7.717. View

18.

Sieving P, Caruso R, Tao W, Coleman H, Thompson D, Fullmer K . Ciliary neurotrophic factor (CNTF) for human retinal degeneration: phase I trial of CNTF delivered by encapsulated cell intraocular implants. Proc Natl Acad Sci U S A. 2006; 103(10):3896-901. PMC: 1383495. DOI: 10.1073/pnas.0600236103. View

19.

Kauper K, McGovern C, Sherman S, Heatherton P, Rapoza R, Stabila P . Two-year intraocular delivery of ciliary neurotrophic factor by encapsulated cell technology implants in patients with chronic retinal degenerative diseases. Invest Ophthalmol Vis Sci. 2012; 53(12):7484-91. DOI: 10.1167/iovs.12-9970. View

20.

Chew E, Clemons T, Jaffe G, Johnson C, Farsiu S, Lad E . Effect of Ciliary Neurotrophic Factor on Retinal Neurodegeneration in Patients with Macular Telangiectasia Type 2: A Randomized Clinical Trial. Ophthalmology. 2018; 126(4):540-549. PMC: 8365464. DOI: 10.1016/j.ophtha.2018.09.041. View